2022
DOI: 10.1016/j.eprac.2022.03.010
|View full text |Cite
|
Sign up to set email alerts
|

American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

4
619
0
58

Year Published

2022
2022
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 554 publications
(681 citation statements)
references
References 387 publications
4
619
0
58
Order By: Relevance
“…Prospective evaluations of potential biomarkers in humans require further evaluation. However, screening guidelines for NAFLD recently released by the American Association of Clinical Endocrinology recommend calculation of a fibrosis-4 (FIB-4) index for high-risk patients [ 45 ] in primary care or endocrinology outpatient settings. This is noteworthy as platelet levels are a crucial component of FIB-4 index calculations, and our omic data-driven mechanistic hypotheses predict changes to risk of thrombosis as shown by DE of 15 thrombosis-related traits across all datasets ( Table S3 ).…”
Section: Discussionmentioning
confidence: 99%
“…Prospective evaluations of potential biomarkers in humans require further evaluation. However, screening guidelines for NAFLD recently released by the American Association of Clinical Endocrinology recommend calculation of a fibrosis-4 (FIB-4) index for high-risk patients [ 45 ] in primary care or endocrinology outpatient settings. This is noteworthy as platelet levels are a crucial component of FIB-4 index calculations, and our omic data-driven mechanistic hypotheses predict changes to risk of thrombosis as shown by DE of 15 thrombosis-related traits across all datasets ( Table S3 ).…”
Section: Discussionmentioning
confidence: 99%
“…Despite its usefulness, an abdominal ultrasound cannot be available for every primary care setting or for population-based screening. In the 2022 clinical practice guideline by the American Association of Clinical Endocrinology and American Association for the Study of Liver Diseases [23], The area under the curve of the fatty liver index was 0.648 (0.624 to 0.671), and that of the xgBoost model was 0.723 (0.701 to 0.744).…”
Section: Discussionmentioning
confidence: 99%
“…Despite its usefulness, an abdominal ultrasound cannot be available for every primary care setting or for population-based screening. In the 2022 clinical practice guideline by the American Association of Clinical Endocrinology and American Association for the Study of Liver Diseases [ 23 ], screening high-risk patients (prediabetes, type 2 diabetes, obesity, and/or metabolic syndromes) with noninvasive biomarkers such as the fatty liver index is recommended, followed by referral ultrasound examination. Such two-step screening is feasible, and may reduce screening time and costs [ 24 ].…”
Section: Discussionmentioning
confidence: 99%
“…To evaluate the probability of advanced liver fibrosis in patients with NAFLD, the NAFLD fibrosis score (NFS) and Fibrosis-4 (FIB-4) were applied [ 27 ]. NFS and FIB-4 were calculated using the following formulas: NFS = −1.675 + 0.037 × age (years) + 0.094 × BMI (kg/m 2 ) + 1.13 × impaired fasting glucose (IFG) or diabetes (yes = 1, no = 0) + 0.99 × aspartate aminotransferase (AST) (U/L)/alanine aminotransferase (ALT) (U/L) − 0.013 × platelet (10 9 /L) − 0.66 × albumin (g/dL); FIB-4 = age (years) × AST (U/L)/[platelet (10 9 /L) × ALT ½ (U/L)].…”
Section: Methodsmentioning
confidence: 99%